NCT02994888View on ClinicalTrials.gov

PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer

CompletedOBSERVATIONAL
Enrollment

47

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab

All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression

Trial Locations (1)

SM2 5PT

The Royal Marsden NHS Foundation Trust, Surrey

All Listed Sponsors
lead

Royal Marsden NHS Foundation Trust

OTHER

NCT02994888 - PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter